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Abstract: Treatment guidelines from the American Academy of Child and Adolescent 
  Psychiatry and the American Academy of Pediatrics state that stimulant medications have the 
most evidence for safety and efficacy in the treatment of childhood attention deficit hyperactivity 
disorder (ADHD). Longer-acting stimulants are thus considered as first-line for management 
of ADHD symptoms. Over the years, concerns about the abuse potential of stimulants have led 
to the development of alternative formulations of these agents. One such recent development, 
lisdexamfetamine (LDX) was FDA approved for treating ADHD in children in early 2007 and 
in adults in early 2008. LDX is a prodrug, which when orally ingested, is converted to l-lysine 
and active d-amphetamine, which is responsible for its therapeutic activity. This unique for-
mulation may lead to a possible reduction of the abuse potential, by bypassing the first-pass 
metabolism. In fact, a statistically significant difference for the ‘liking’ effects on the Drug 
Questionnaire Response has been reported with intravenous LDX compared to d-amphetamine. 
LDX appears to have an efficacy and tolerability profile comparable to other extended-release 
stimulant formulations used to treat ADHD, but reduced potential for abuse-related liking 
effects when compared to equivalent amounts of immediate-release d-amphetamine. The most 
common adverse events include decreased appetite, insomnia, upper abdominal pain, headache, 
irritability, weight loss, and nausea.
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Introduction
Treatment guidelines from the American Academy of Child and Adolescent Psychiatry 
and the American Academy of Pediatrics state that stimulant medications have the 
most evidence for safety and efficacy in the treatment of childhood attention deficit 
hyperactivity disorder (ADHD). Longer-acting stimulants are thus considered as first 
line for management of ADHD symptoms.1,2 Over the years, concerns related to the 
abuse potential of stimulants have led to the development of alternative formulations 
of these agents.3
One such recent development, lisdexamfetamine (LDX) was approved by the Food 
and Drug Administration (FDA) for treating ADHD in children in early 2007 and in 
adults in early 2008. LDX is a prodrug, which when orally ingested, is converted to 
l-lysine and active d-amphetamine, which is responsible for its therapeutic activity. 
This unique formulation may lead to a possible reduction of the abuse potential, by 
bypassing the first-pass metabolism. In fact, a statistically significant difference for 
the ‘liking’ effects on the Drug Questionnaire Response, has been reported with 
  intravenous LDX compared to d-amphetamine.4Neuropsychiatric Disease and Treatment 2010:6 274
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ADHD is a common childhood neurobehavioral disorder 
with an estimated prevalence of 7% to 10% in school-aged 
children.5,6 Childhood ADHD presents with hyperactivity-
impulsivity and/or inattentive behaviors which occur more 
commonly and are of a greater severity than would normally 
be seen in children of similar age and developmental level. 
According to the National Comorbidity Survey, symptoms 
of ADHD persist into adolescence and adulthood severely 
impairing function in 37% to 85% of those affected.6
Stimulants are regarded as first-line pharmacotherapy 
in children and adults and are currently the most widely 
prescribed medications for the treatment of ADHD.7,8 There 
is evidence to suggest that the lack of consistency and 
predictability in their bioavailability may result in variable 
efficacy and duration of effect.9–11 While these medications 
are effective and largely safe, they may mediate reinforc-
ing effects, which has often led to concerns about abuse 
  potential.12 Unmet therapeutic needs in ADHD include 
  having a consistent delivery of the medication, adequate 
duration of action, and also reduced potential for abuse.
LDX is the first long-acting prodrug stimulant to be 
developed and provides a long acting duration of effect that 
is consistent throughout the day, with a potential for less 
abuse compared to equivalent amounts of immediate-release 
d-amphetamine.13,14 Prodrugs are inactive compounds that 
require in vivo conversion to release therapeutically active 
medications. Children 6 to 12 years of age who were treated 
with LDX showed improvement of ADHD symptoms as early 
as the first week of treatment, with tolerance of side effects 
in short-term, placebo-controlled studies.10,14
LDX is a therapeutically inactive molecule which is con-
verted to l-lysine, a naturally occurring essential amino acid, 
and active d-amphetamine after ingestion, the latter of which 
is responsible for the therapeutic activity. The conversion of 
LDX to d-amphetamine is not affected by gastrointestinal pH 
and is unlikely to be affected by alterations in normal gastro-
intestinal transit times.16 Another pharmacokinetic interaction 
study indicated a lack of drug interaction with concomitant 
administration proton pump inhibitor omeprazole with LDX. 
LDX can thus be co-administered with medications that alter 
gastrointestinal pH.
LDX was designed to have efficacy and tolerability com-
parable to other extended-release stimulant formulations used 
to treat ADHD, but with reduced potential for abuse. It has a 
chemical designation of (2S)-2,6-diamino-N-[(1S)-1-methyl-
2-phenylethyl] hexanamide dimethanesulfonate and the 
corresponding molecular formula is C15H25N3O•(CH4O3S2). 
LDX has a molecular weight of 455.60. LDX is formulated 
as a white water soluble powder and is only available in cap-
sules, containing 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, and 
70 mg of LDX.17 LDX consists of d-amphetamine covalently 
attached to an essential amino acid, L-lysine.
Mechanism of action
LDX is a prodrug which is pharmacologically inactive and 
undergoes biotransformation before exhibiting its pharmaco-
logical effects. After oral ingestion, LDX undergoes first pass 
intestinal and/or hepatic metabolism, the exact mechanism 
of which has not yet been elucidated. It is quickly absorbed 
from the gastrointestinal tract and converted to L-lysine 
and the active drug moiety d-amphetamine via enzymatic 
cleavage of the amide linkage. Preclinical studies propose 
that the systemic circulation is the primary site (90%) of 
this conversion.16,17 This is evident from the concentration-
time profile of LDX, which displays a rapid peak plasma 
concentration (Tmax 1 hour) as well as the simultaneous slow 
rise of d-amphetamine concentrations, with peak levels of 
d-amphetamine found 3.5 hours after oral ingestion. Thus the 
contribution of the gastrointestinal tract to the conversion of 
LDX to d-amphetamine is low and not affected by gastroin-
testinal pH or gastrointestinal transit times. The result is the 
conversion of LDX to d-amphetamine which mediates its 
therapeutic effect by blocking norepinephrine and dopamine 
reuptake into presynaptic neurons and increasing their release 
into the extraneuronal space.
Pharmacokinetics
After oral administration, LDX is rapidly absorbed from the 
gastrointestinal tract and is converted to d-amphetamine and 
L-lysine. In a Phase I, open label, crossover study where 
18 children with ADHD and aged 6 to 12 years, fasted for 
8 hours and then were given a single oral dose of 30-, 50- or 
70-mg dose of LDX. The Tmax of LDX in this study was found 
to be 1 hour and the Tmax of d-amphetamine was approxi-
mately 3.5 hours. This suggests that the systemic circulation 
is the site of conversion.17 D-amphetamine pharmacokinet-
ics following single-dose oral administration of LDX was 
found to be linear over the dose range of 30 to 70 mg in 6- to 
12-year-old children with no effect observed in the area under 
the concentration – time curve (AUC).
Data from a Phase I, single-dose, randomized, open-label 
crossover study in adults administered a single-dose of 70 mg 
after either fasting, consuming a high fat meal, or ingesting a 
solution containing capsule contents, resulted in equivalent 
bioavailabilities based on maximum drug concentration 
(Cmax) and AUC. However, the fed patients experienced Tmax Neuropsychiatric Disease and Treatment 2010:6 275
Lisdexamfetamine for ADHD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
which was prolonged by 1 hour as compared to the patients 
who had fasted.18
Food does not affect absorption of LDX and delays 
Cmax by 1 hour or less, therefore LDX can be given with 
breakfast without affecting therapeutic effect. In contrast, 
food prolonged the Tmax of d-amphetamine from extended-
release mixed amphetamine salts (MAS XR) by 2.5 hours 
compared with the fasted state.19 A Phase II, randomized, 
multi-center, double blind trial found that the Tmax of LDX 
was 3.5 times less variable than with MAS XR, based on 
coefficients of variation of 15.33% for LDX and 52.77% 
for MAS XR. Thus patients who took 70 mg of LDX had a 
more predictable release of d-amphetamine than those who 
took 30 mg of MAS XR. In addition, the solubility, conver-
sion for LDX to d-amphetamine, and absorption of LDX is 
not affected by variations in gastric pH.10 Pharmacokinetics 
of d-amphetamine were found to be similar in pediatric and 
adolescent ADHD patients and healthy adult volunteers.
It is thought that LDX is not metabolized by cytochrome 
P450 enzymes, and hence, it does not inhibit the majority of 
these enzymes.20 Krishnan’s investigation of the P450 inter-
action with LDX demonstrated that incubation of LDX with 
human liver microsomes did not produce concentration-depen-
dent or mechanism-based inhibition of any of the isoenzymes 
under investigation: CYP1A2, CYP2A6, CYP2B6, CYP2C9, 
CYP2C19, CYP2D6, and CYP3A4. While active d-amphet-
amine is finally metabolized to benzoic acid and hippuric acid, 
results from this study indicate that any drug interactions would 
likely be caused by amphetamine and its metabolites rather 
than the intact LDX prodrug. The drug reaches steady-state 
concentrations in 2 to 3 days.21
The recommended initial dose of LDX is 30 mg daily, 
independent of prior stimulant treatments, the patient’s age, 
and weight. The therapy should be titrated in 10-mg incre-
ments at weekly intervals until therapeutic effect is achieved.17 
It is administered in the morning, to limit the adverse effect 
on sleep and can be given with or without food. LDX doses 
of 30, 50, and 70 mg are equivalent in base content of d-
amphetamine to extended-release MAS XR doses of 10, 20, 
and 30 mg, respectively.15 Doses greater than 70 mg/day have 
not been studied in children or adults.
Efficacy studies
Two short-term double-blind, multi-center clinical studies in 
school aged children who met DSM-IV-TR criteria for ADHD 
assessed the efficacy and safety profile of once daily oral 
LDX.10,15 The first study by Biederman et al was a phase II 
multicenter, double blind, placebo and active controlled 3-
treatment 3-period crossover study10 in 52 children aged 6 to 
12 years. The study was conducted in a controlled classroom 
environment with children with a mean age of 9.1 years (SD 
1.7 years) in whom the time from initial ADHD diagnosis 
was a mean of 3.3 years (SD 2.3 years). Exclusion criteria 
included comorbid medical and psychiatric disorders which 
could affect efficacy or tolerability of the stimulants; his-
tory of seizures within the past 2 years; significant labora-
tory abnormalities; history of drug abuse; current use of 
central nervous system medications; history of allergy to 
stimulants; and hyperthyroidism, tic disorders, or cardiac 
disorders.10 Inclusion criteria required the capacity to follow 
classroom instructions, age-appropriate academic functional 
capacity and a history of adequate response to stable dose 
stimulant medication of at least 1 month during the previous 
6 months.
The subjects in this study initially received MAS-XR 
for 3 weeks. Based on response as measured on the Clinical 
Global Impression (CGI) score, interviews with parents and 
safety data, the doses were either kept the same, or titrated up 
or downwards by 10-mg increments, with a minimum dose 
of 10 mg/day. Efforts to compare placebo, MAS XR and 
LDX, were accomplished by assigning patients to 3 cohorts 
based on the initial titration phase delineating the optimal 
dose of MAS XR. The first group received placebo, MAS 
XR 10 mg/day and LDX 30 mg/day each for 1 week. The 
second group was given placebo, MAS XR 20 mg/day and 
LDX 50 mg/day each for 1 week. The third group received 
placebo, MAS XR 30 mg/day and LDX 70 mg/day each 
for 1 week. The Swanson, Kotkin, Agler, M-Flynn, and 
Pelham (SKAMP) scale and Permanent Product Measure 
of Performance Derived Measures (PERMP) were used 
as primary efficacy measures to compare improvement in 
ADHD symptoms among the three agents. This study found 
that both MAS XR and LDX produced similar improvements, 
both of which were superior at all doses as compared to pla-
cebo. Adverse events were reported in 16% of LDX patients, 
18% of MAS XR patients, and 15% of placebo patients. The 
most common side effects were insomnia (8%), decreased 
appetite (6%) and anorexia (4%).
The second study was conducted by Biederman et al. This 
was a phase III, randomized, placebo-controlled, double-blind 
trial that included 290 children between the ages of 6 and 
12 years, parallel group study (201 boys, 89 girls) diagnosed 
with either combined or hyperactive subtypes of ADHD.15 
After a 1-week washout period, these subjects were randomly 
assigned to received LDX (doses of 30 mg/day, 50 mg/day 
or 70 mg/day) or placebo for 4 weeks. Groups consisted Neuropsychiatric Disease and Treatment 2010:6 276
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of 94.4%, 95.9%, 97.3%, and 95.8% of patients diagnosed 
with combined type ADHD, respectively. Improvement was 
measured by change from baseline on the ADHD Rating 
Scale Version IV (ADHD-RS-IV), which was considered the 
primary efficacy end point. ADHD-RS IV scores decreased 
by 50% to 59% in all three LDX groups, with the greatest 
improvement noted in the 70 mg/day group, as compared to a 
15% reduction in the placebo group. Distinctions within each 
dose group, comparing the improvements in the combined 
type vs the hyperactive subtype of ADHD were not made in 
this study, although each group was predominately ADHD 
combined type. In addition, this study also looked at parental 
perception of symptom improvement as a secondary effi-
cacy outcome measure using a change from baseline on the 
Conner’s Parent Rating Scale-Revised Short Form (CPRS-R). 
This scale assessed parental perception of ADHD symptoms 
of children on LDX and reported that ADHD symptoms were 
significantly improved at each time point with all LDX daily 
doses. Another secondary efficacy outcome measure, the 
CGI-I score, showed 70% of patients in the active treatment 
groups were “very much improved or much improved” at 10 
AM, 2 PM, and 6 PM compared with 18% observed in the 
placebo group (P  0.001). These results indicate that LDX 
may be effective throughout the day.15
Safety and tolerability
Efficacy and tolerability profiles in the same phase III study 
by Biederman et al15 in school-aged children with ADHD 
was assessed using tolerability assessments which consisted 
of patient interview and observation, electrocardiogram 
(ECG), physical examination, and laboratory and biochemi-
cal tests. Researchers reported that treatment with LDX was 
not associated with any significant changes in mean ECG 
parameters, laboratory values, and systolic and diastolic 
blood pressures. Adverse events were experienced in 72% 
of the children who received LDX 30 mg, 68% of children 
who received 50 mg and 84% of children who received 
LDX 60 mg. Amongst the placebo group, 47% of patients 
reported adverse events.15
Over 95% of the adverse events for all doses of LDX 
were mild or moderate and consisted of: decreased appetite 
(39% of subjects in the LDX group vs 4% with placebo), 
insomnia (18.8% vs 3%), headache (11.9% vs 10%), upper 
abdominal pain (11.9% vs 6%), and irritability (10% vs 0%). 
Most adverse events began during the first week of treatment. 
No severe adverse events were observed and the majority of 
all events reported had resolved within 4 weeks of continued 
therapy.
Although LDX treatment was not associated with 
  significant changes in mean ECG parameters, this study 
found that children on LDX had a significant increase in 
mean heart rate when compared to the placebo group. It was 
also reported that the highest placebo-adjusted mean increase 
of 4 to 5 beats per minute occurred with the 70-mg dose at 
endpoint, although no significant differences were reported 
at each treatment week.
In the phase II multicenter, double blind, placebo and 
active controlled 3-treatment, 3-period crossover study in 
a controlled classroom environment by Biederman et al10 
three cohorts received LDX, MAS XR, and placebo once 
daily for 1 week. During the open label part dose titration 
with MAS XR the adverse events reported were headache 
(15%), decreased appetite (14%), insomnia (10%), abdominal 
pain (6%), upper respiratory infection (4%), affect lability 
(4%), anorexia (2%), and vomiting (2%). During the double 
blind part of the study, the adverse events for LDX, MAS 
XR and placebo are reported respectively: decreased appetite 
(8%, 2%, 2%), decreased appetite (6%, 4%, 0%), upper respi-
rator tract infection (2%, 2%, 0%), vomiting (0%, 2%, 4%), 
upper abdominal pain (0%, 4%, 2%).
In a poison control review of adverse events to LDX 
  conducted in 5 poison centers spread across 8 states, there 
were 81 reported cases of LDX ingestion, of which 28 
patients or 35% of those who ingested experienced adverse 
effects.24 Previously reported rates for amphetamines were 
3.1%. Of those patients most (79%) involved first ingestions 
and 86% of cases were within the first week of treatment with 
LDX. The most commonly reported symptoms were agitation 
(53%), tachycardia (73%), dystonia (47%), insomnia (20%), 
hallucinations (20%) and chest pain (13%).
A long-term study of the safety, tolerability and effi-
cacy of LDX was done by Findling et al and consisted of 
272 children ages 6 to 12 years who were diagnosed with 
ADHD by DSM-IV-TR criteria and followed for 12 months.14 
This study was predominately with white males aged 7 to 
11 years diagnosed with ADHD combined type and had 
participated in prior trials with an average disease duration 
of 2.3 years. ADHD-RS scores improved by a mean of 27.2 
points (P  0.0001) with maintenance of improvements 
during the first 4 weeks throughout the study. Of the 147 
children who completed the study, 80% of children at 
endpoint and 95% of completers were rated “improved” 
based on CGI-I scale.
Over 78% of children experienced adverse events during 
the course of the study. These adverse events were considered 
mild to moderate, and occurred mostly in the first 4 weeks Neuropsychiatric Disease and Treatment 2010:6 277
Lisdexamfetamine for ADHD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
of treatment. Over the course of the study, 213 (78%) of 
272 treated children experienced a total of 987 treatment-
emergent adverse events, of which 97.5% were mild or 
moderate in severity. These events occurred during the first 
2 months of treatment and after 4 months, with an incidence 
of 5% by 4 months. Treatment-emergent adverse events 
occurring in 5% of children included decreased appetite 
(33%), headache (18%), weight loss (18%), insomnia (17%), 
upper abdominal pain (11%), upper respiratory tract infection 
(11%), irritability (10%), nasopharyngitis (10%), vomiting 
(9%), cough (7%) and influenza (6%). Of the 272 children 
treated with LDX, 25 (9%) discontinued treatment due to 
adverse events. Most commonly (1%) reasons for discon-
tinuation were irritability, aggressive behavior, and decreased 
appetite (n = 3 each; 1.1%).
This is the only long-term safety and tolerability study 
with LDX in children with ADHD. It did not use an objec-
tive assessment tool in recording adverse events but instead 
relied on observation for gathering of adverse event data, 
thus leading to a potential underreporting of adverse events. 
Furthermore, most of the patients in this study had received 
LDX in a previous trial. Thus it is possible that those who 
experienced acute adverse events in the previous study did 
not subsequently chose to continue into the current study and 
data regarding their adverse events are not included in this 
open label study. This would lead to a lower rate of adverse 
events reported. In addition, due to the majority of patients 
being male (69%) and white (53%), more trials looking at 
the relative benefit of LDX in female patients and patients 
with different ethnic backgrounds, as well as those with co-
morbid psychiatric illnesses are needed.
There may be unknown long-term complications with 
using LDX as with other stimulants, and clinicians should 
utilize the patient’s medical history, family history, ECG, 
blood pressure and pulse as well as a thorough physical 
examination to assess the presence of cardiovascular disease 
prior to prescribing stimulants. In August 2008, the American 
Academy of Pediatrics (AAP) issued a recommendation stat-
ing that routine use of ECGs in children receiving medica-
tions for ADHD is not warranted. A joint statement by AAP 
and the American Heart Association states that ECGs are 
not mandatory, but should be performed at the physician’s 
discretion.25
The warning section of the prescribing information 
includes many of the same precautions as other stimulants 
used to treat ADHD. LDX has a black box warning pointing 
out the possibility of abuse of amphetamines, the possibility 
of drug dependence, and the potential for sudden cardiac 
death and adverse events when misused. It also warns against 
the use of LDX and other stimulants in patients with advanced 
atherosclerosis, structural cardiac abnormalities, moderate-
severe hypertension, hyperthyroidism, glaucoma, history of 
agitation, and patients with a history of drug abuse.17
Abuse potential
LDX is categorized as a Schedule II Controlled Substance 
according to the United States Drug Enforcement Agency. 
To date, there are two placebo controlled clinical studies of 
the oral abuse liability of LDX22–23 and 1 placebo controlled 
trial of IV abuse liability,4 all of them performed using 
healthy adult subjects with a diagnosis of stimulant abuse 
based on DSM-IV-TR criteria. Results of all three studies 
report a lower abuse potential of LDX when compared to 
immediate-release d-amphetamine sulfate.
One of the initial studies of abuse liability of oral LDX 
was a double-blind, placebo- and active-controlled study with 
a single-dose crossover design which evaluated the safety, 
tolerability and abuse liability of intravenously administered 
LDX in group of 12 healthy adult volunteers who met criteria 
of stimulant abuse by DSM-IV-TR at the time of the study. 
Subjects in this study received single oral doses of 30 to 
150 mg LDX, placebo, or immediate release d-amphetamine 
sulfate in equivalent doses. LDX at equivalent or higher in 
d-amphetamine content caused less euphoria and drug liking, 
with a later mean peak effect relative to the d-amphetamine 
as measured on the Drug Rating Questionnaire-Subjects 
(DRQS) and the Drug Rating Questionnaire-Observer 
(DRQO). Subjects reported euphoria within 15 minutes 
of d-amphetamine, whereas subjects receiving LDX did 
not show a statistically significant difference compared to 
  placebo in liking effects.
Another abuse liability study by Jasinski et al23 was a 
double-blind, randomized, placebo- and active-controlled, 
crossover study. This study was designed to evaluate the 
likeability, safety and abuse liability of oral LDX in healthy 
adult volunteers with a DSM-IV-TR diagnosis of stimulant 
abuse at the time of the study. It enrolled 36 adult (30 male 
and 6 female) stimulant abusers and compared onset and lik-
ing effects of LDX 50 mg, 100 mg, and 150 mg as compared 
to d-amphetamine 40 mg (equivalent to LDX 100 mg) and 
placebo. The study findings indicated that LDX attenuates 
the onset and intensity of subjective drug liking effects as 
measured by the DRQS. Furthermore, the liking effects of 
LDX  100 mg were not significantly different from placebo. 
At doses of LDX 150 mg, the liking effects were greater than 
placebo and similar to d-amphetamine 40 mg. This may be Neuropsychiatric Disease and Treatment 2010:6 278
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in part due to the mean peak effect of the liking effects in 
LDX which was delayed as compared to d-amphetamine. 
The attenuated liking scale scores suggest that LDX may be 
less reinforcing than an equivalent dose of d-amphetamine.
The abuse liability of IV LDX 25 mg and 50 mg was 
compared with IV d-amphetamine sulfate 10 mg or 20 mg, 
and with placebo in 12 healthy, non-ADHD volunteers with 
a diagnosis of stimulant abuse based on DSM-IV-TR criteria 
in a randomized, single-center, double-blind, 3-way cross-
over study. Subjects receiving IV LDX 25 mg reported no 
amphetamine-like effects, and those receiving LDX 50 mg 
did not report drug liking scores comparable with placebo. 
D-amphetamine sulfate 20 mg displayed significant drug-
liking scores. In this study, 89% of subjects reported that 
they would not choose to take LDX again. To date, there 
are no studies studying the oral or IV LDX abuse liability 
in healthy adults without a diagnosis of stimulant abuse by 
DSM-IV-TR.4
Contraindications and use  
in special populations
LDX should be used with caution in patients with known 
hypersensitivity or idiosyncratic reactions to sympatho-
mimetic amines, hyperthyroidism, glaucoma, moderate to 
severe hypertension, advanced arteriosclerosis, and patients 
with a history of drug abuse. LDX is contraindicated for 
14 days after discontinuation of monoamine oxidase inhibi-
tor use. LDX has not been studied humans in pregnancy 
and is a Pregnancy Category C. LDX should be used very 
cautiously in pregnancy, and only in situations where the 
benefit outweighs the risk to the fetus as currently no adequate 
and well-controlled studies in pregnant women have been 
performed. To date, there has been one report of severe 
congenital bony deformity, tracheo-esophageal fistula, and 
anal atresia (VATER association) in a baby born to a woman 
taking LDX with lovastatin during the first trimester of 
pregnancy. The package insert for LDX states that while it 
has not been studied in pregnant women amphetamines are 
secreted in breast milk. Pregnant females are at increased 
risk of premature delivery, giving birth to infants with low 
birth weights, and may give birth to infants with neonatal 
withdrawal related dysphoria and agitation.17 LDX has not 
been studied in the geriatric population.
Conclusions
LDX is the first FDA approved long acting prodrug 
amphetamine stimulant in children aged 6 to 12 years and 
adults with ADHD. It consists of a moiety of L-lysine and 
d-amphetamine which requires proteolytic cleavage before 
the active d-amphetamine is released. It has similar efficacy 
and tolerability but less potential for abuse than equivalent 
amounts of immediate release dextroamphetamine. Abuse 
potential of LDX appears attenuated by the prodrug struc-
ture, slow-release formulation, longer Tmax, and a more 
consistent effect throughout the day. LDX has been shown 
to be less likable than immediate release d-amphetamine 
based on drug liking effects as measured by the Drug Rating 
Questionnaire-Subjects and the Drug Rating Questionnaire-
Observer in studies of LDX. Therefore, LDX may be part of 
a comprehensive treatment plan for ADHD which includes 
educational, psychological, and social interventions.
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